Abstract:BackgroundTreatment options for patients with triple-negative breast cancer (TNBC) remain limited to mainstay therapies owing to a lack of efficacious therapeutic targets. Accordingly, there is an urgent need to discover and identify novel molecular targets for the treatment and diagnosis of this disease. In this study, we analyzed the correlation of telomerase reverse transcriptase (TERT) methylation status with TERT expression, prognosis, and immune infiltration in TNBC and identified the role of TERT methylation in the regulation TNBC prognosis and immunotherapy.MethodsData relating to the transcriptome, clinicopathological characteristics and methylation of TNBC patients were obtained from The Cancer Genome Atlas (TCGA) database. TERT expression levels and differential methylation sites (DMSs) were detected. The correlations between TERT expression and DMSs were calculated. Kaplan–Meier curves was plotted to analyze the relationship between the survival of TNBC patients and the DMSs. The correlations of DMSs and TERT expression with several immunological characteristics of immune microenvironment (immune cell infiltration, immunomodulators, immune-related biological pathways, and immune checkpoints) were assessed. The results were validated using 40 TNBC patients from Sun Yat-sen University Cancer Center (SYSUCC).ResultsSix DMSs were identified. Among them, four sites (cg11625005, cg07380026, cg17166338, and cg26006951) were within the TERT promoter, in which two sites (cg07380026 and cg26006951) were significantly related to the prognosis of patients with TNBC. Further validation using 40 TNBC samples from SYSUCC showed that the high methylation of the cg26006951 CpG site was associated with poor survival prognosis (P=0.0022). TERT expression was significantly correlated with pathological N stage and clinical stage, and cg07380026 were significantly associated with pathological T and N stages in the TCGA cohort. Moreover, the methylation site cg26006951, cg07380026 and TERT expression were significantly correlated with immune cell infiltration, common immunomodulators, and the level of the immune checkpoint receptor lymphocyte activation gene 3 (LAG-3) in TNBC patients.ConclusionTERT promotertypermethylation plays an important role in TERT expression regulation and tumor microenvironment in TNBC. It is associated with overall survival and LAG-3 expression. TERT promoter hypermethylation may be a potential molecular biomarker for predicting response to the TERT inhibitors and immune checkpoint inhibitors in TNBC.

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy

TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma

Multi-parameter MRI Based Radiomics Nomogram for Predicting Telomerase Reverse Transcriptase Promoter Mutation and Prognosis in Glioblastoma.

TERT Genetic Mutations as Prognostic Marker in Glioma

Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer

Association of human telomerase reverse transcriptase promoter mutation with unfavorable prognosis in glioma: A systematic review and meta-analysis

Prognostic Value and Immune Landscapes of TERT Promoter Methylation in Triple Negative Breast Cancer

Paradoxical Prognostic Impact of TERT Promoter Mutations in Gliomas Depends on Different Histological and Genetic Backgrounds.

The Combined Signatures of Telomere and Immune Cell Landscape Provide a Prognostic and Therapeutic Biomarker in Glioma.

Noninvasive Prediction of TERT Promoter Mutations in High-Grade Glioma by Radiomics Analysis Based on Multiparameter MRI

Human TERT promoter mutations as a prognostic biomarker in glioma

TERT Mutations-Associated Alterations in Clinical Characteristics, Immune Environment and Therapy Response in Glioblastomas

Prediction of TERT mutation status in gliomas using conventional MRI radiogenomic features

TERT Promoter Mutations Contribute to Subset Prognostication of Lower-Grade Gliomas

Construction of a telomere-related gene signature to predict prognosis and immune landscape for glioma

Conventional Magnetic Resonance Imaging–based Radiomic Signature Predicts Telomerase Reverse Transcriptase Promoter Mutation Status in Grade II and III Gliomas

Prognostic stratification of patients with primary glioblastoma based on mutations of TERT promoter and IDH1

TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment

Development of a tumor microenvironment‐related prognostic signature in glioma to predict immune landscape and potential therapeutic drugs

TERT Promoter Mutations and Long Telomere Length Predict Poor Survival and Radiotherapy Resistance in Gliomas

Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival